Circulating and Urinary Tumour DNA in Urothelial Carcinoma - Upper Tract, Lower Tract and Metastatic Disease

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2023 Mar 28

PMID 36977797

Authors

Kyle M Rose

Heather L Huelster

Joshua J Meeks

Bishoy M Faltas

Guru P Sonpavde

Seth P Lerner

Jeffrey S Ross

Philippe E Spiess

G Daniel Grass

Rohit K Jain

Ashish M Kamat

Aram Vosoughi

Liang Wang

Xuefeng Wang

Roger Li

Affiliations

Soon will be listed here.

Abstract

Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular heterogeneity observed in many studies. Among rapidly advancing genomic sequencing technologies, non-invasive liquid biopsy has emerged as a promising diagnostic tool to reproduce tumour genomics, and has shown potential to be integrated in several aspects of clinical care. In urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and urinary tumour DNA (utDNA) have been investigated as a surrogates for tumour biopsies and might bridge many shortfalls currently faced by clinicians. Both ctDNA and utDNA seem really promising in urothelial carcinoma diagnosis, staging and prognosis, response to therapy monitoring, detection of minimal residual disease and surveillance. The use of liquid biopsies in patients with urothelial carcinoma could further advance precision medicine in this population, facilitating personalized patient monitoring through non-invasive assays.

Citing Articles

Clinical utility of liquid biopsy in bladder cancer: The beginning of a new era.

Jia E, Agarwal G J Liq Biopsy. 2025; 6:100271.

PMID: 40027318 PMC: 11863694. DOI: 10.1016/j.jlb.2024.100271.

Mapping the chromothripsis landscape in urothelial carcinoma unravels great intratumoral and intertumoral heterogeneity.

Zeng Y, Lv W, Tao H, Li C, Jiang S, Liang Y iScience. 2025; 28(1):111510.

PMID: 39790556 PMC: 11714673. DOI: 10.1016/j.isci.2024.111510.

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.

Klumper N, Cox A, Sjodahl G, Roghmann F, Bolenz C, Hartmann A Nat Rev Urol. 2024; .

PMID: 39472646 DOI: 10.1038/s41585-024-00951-2.

A Novel Urine DNA Predictor for Noninvasive Early Diagnosis and Monitoring Minimal Residual Disease of Upper Tract Urothelial Carcinoma.

Zuo W, Guo X, Zhang J, Yu W, Zhang Y, Cheng H Cancer Med. 2024; 13(20):e70346.

PMID: 39440792 PMC: 11497171. DOI: 10.1002/cam4.70346.

Nature Reviews Urology: evolving with the field for 20 years.

Nat Rev Urol. 2024; 21(11):642-643.

PMID: 39394367 DOI: 10.1038/s41585-024-00957-w.

References

Yoshida T, Kates M, Fujita K, Bivalacqua T, McConkey D . Predictive biomarkers for drug response in bladder cancer. Int J Urol. 2019; 26(11):1044-1053. DOI: 10.1111/iju.14082. View

Green E, Li R, Albiges L, Choueiri T, Freedman M, Pal S . Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021; 4(6):893-903. DOI: 10.1016/j.euo.2021.04.005. View

Anker P, Stroun M, Maurice P . Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res. 1975; 35(9):2375-82. View

Snyder M, Kircher M, Hill A, Daza R, Shendure J . Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016; 164(1-2):57-68. PMC: 4715266. DOI: 10.1016/j.cell.2015.11.050. View

Ulz P, Thallinger G, Auer M, Graf R, Kashofer K, Jahn S . Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016; 48(10):1273-8. DOI: 10.1038/ng.3648. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Utting M, Werner W, Dahse R, Schubert J, Junker K . Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002; 8(1):35-40. View

Diaz Jr L, Bardelli A . Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6):579-86. PMC: 4820760. DOI: 10.1200/JCO.2012.45.2011. View

Smith A, Deal A, Woods M, Wallen E, Pruthi R, Chen R . Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2013; 114(5):719-26. DOI: 10.1111/bju.12601. View

10.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

11.

Chamie K, Litwin M, Bassett J, Daskivich T, Lai J, Hanley J . Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013; 119(17):3219-27. PMC: 3773281. DOI: 10.1002/cncr.28147. View

12.

Kompier L, Lurkin I, van der Aa M, van Rhijn B, van der Kwast T, Zwarthoff E . FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010; 5(11):e13821. PMC: 2972209. DOI: 10.1371/journal.pone.0013821. View

13.

Pietzak E, Bagrodia A, Cha E, Drill E, Iyer G, Isharwal S . Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur Urol. 2017; 72(6):952-959. PMC: 6007852. DOI: 10.1016/j.eururo.2017.05.032. View

14.

Hosen M, Forey N, Durand G, Voegele C, Bilici S, Avogbe P . Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. Cancers (Basel). 2020; 12(12). PMC: 7761513. DOI: 10.3390/cancers12123541. View

15.

Li R, Du Y, Chen Z, Xu D, Lin T, Jin S . Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science. 2020; 370(6512):82-89. DOI: 10.1126/science.aba7300. View

16.

Lindskrog S, Prip F, Lamy P, Taber A, Groeneveld C, Birkenkamp-Demtroder K . An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021; 12(1):2301. PMC: 8052448. DOI: 10.1038/s41467-021-22465-w. View

17.

Meeks J, Carneiro B, Pai S, Oberlin D, Rademaker A, Fedorchak K . Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget. 2016; 7(46):75176-75184. PMC: 5342732. DOI: 10.18632/oncotarget.12661. View

18.

Bacon J, Muller D, Ritch E, Annala M, Dugas S, Herberts C . Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. Eur Urol Oncol. 2021; 5(6):677-686. DOI: 10.1016/j.euo.2021.11.002. View

19.

Lamy P, Nordentoft I, Birkenkamp-Demtroder K, Thomsen M, Villesen P, Vang S . Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Res. 2016; 76(19):5894-5906. DOI: 10.1158/0008-5472.CAN-16-0436. View

20.

Robertson A, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack A . Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017; 171(3):540-556.e25. PMC: 5687509. DOI: 10.1016/j.cell.2017.09.007. View